iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
Status:
Recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
This phase I trial studies the best dose and side effects of mesenchymal stromal
cells-derived exosomes with KrasG12D siRNA (iExosomes) in treating participants with
pancreatic cancer with KrasG12D mutation that has spread to other places in the body.
iExosomes may work better at treating pancreatic cancer.